Eton Pharmaceuticals Gets FDA Approval of Rezipres
16 June 2021 - 1:12AM
Dow Jones News
By Colin Kellaher
Eton Pharmaceuticals Inc. on Tuesday said the U.S. Food and Drug
Administration approved the company's Rezipres ephedrine
hydrochloride injection for the treatment of clinically important
hypotension occurring in the setting of anesthesia.
The Deer Park, Ill., drugmaker said Rezipres marks its second
FDA-approved ready-to-use hospital injectable product.
Eton last month said the FDA had turned away its application for
approval of a dehydrated alcohol injection for the treatment of
methanol poisoning, saying it couldn't approve the application in
its current form. Eton at the time said it believes it can address
the agency's concerns in the coming months.
Trading in shares of Eton was halted Tuesday morning.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
June 15, 2021 11:05 ET (15:05 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Eton Pharmaceuticals (NASDAQ:ETON)
Historical Stock Chart
From Apr 2024 to May 2024
Eton Pharmaceuticals (NASDAQ:ETON)
Historical Stock Chart
From May 2023 to May 2024